Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.24.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Operating Expenses        
Research and development $ 2,287,525 $ 1,151,740 $ 5,556,694 $ 4,478,793
General and administrative 1,137,328 1,015,872 3,759,781 4,508,818
Operating Loss (3,424,853) (2,167,612) (9,316,475) (8,987,611)
Other Income (Expense)        
Interest income, net 40,150 85,661 195,065 271,022
Net Loss $ (3,384,703) $ (2,081,951) $ (9,121,410) $ (8,716,589)
Net Loss per Common Share - Basic $ (1.03) $ (1.54) $ (3.13) $ (6.81)
Net Loss per Common Share - Diluted $ (1.03) $ (1.54) $ (3.13) $ (6.81)
Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic 3,275,998 1,350,188 2,909,941 1,279,298
Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Diluted 3,275,998 1,350,188 2,909,941 1,279,298